Evolus to Report Second Quarter 2022 Results and Provide Business Update

Rhea-AI Summary

Evolus, Inc. (NASDAQ: EOLS) will announce its second quarter 2022 financial results on August 2, 2022, before U.S. markets open. A conference call will be held at 9:00 a.m. ET to discuss the results, followed by a Q&A session. Investors can participate by dialing (877) 407-6184 (U.S.) or (201) 389-0877 (international), or via a live webcast accessible on Evolus' website. A replay of the call will be available afterwards. Evolus focuses on the aesthetic neurotoxin market, primarily with its product Jeuveau, designed for beauty consumers.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its second quarter 2022 financial results and provide a business update on Tuesday, August 2, 2022, before the U.S. financial markets open.

Management will host a conference call and live webcast to discuss Evolus’ financial results at 9:00 a.m. ET that same day. A question-and-answer session will follow management’s remarks.

To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect to the live webcast via the link on the Investor Relations page of the Evolus website at www.evolus.com.

Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international). An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau^® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Visit us at www.evolus.com and follow us on LinkedIn, Twitter, Instagram or Facebook.

Jeuveau^® is a registered trademark of Evolus, Inc.
Hi-Pure^™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005401/en/

Investor/Media Contact:

David K. Erickson, Evolus, Inc.

Vice President, Investor Relations

Tel: 949-966-1798

Email: david.erickson@evolus.com

Source: Evolus

FAQ

When will Evolus report its second quarter 2022 financial results?

Evolus will report its second quarter 2022 financial results on August 2, 2022.

What time is the Evolus conference call scheduled for?

The Evolus conference call will take place at 9:00 a.m. ET on August 2, 2022.

How can I participate in the Evolus conference call?

To participate in the Evolus conference call, dial (877) 407-6184 for U.S. calls or (201) 389-0877 for international calls, or connect via the live webcast on the Evolus Investor Relations page.

Where can I find the archived webcast of the Evolus conference call?

The archived webcast of the Evolus conference call will be available on the Investor Relations section of the Evolus website after the call.

What is Evolus' flagship product?

Evolus' flagship product is Jeuveau, a neurotoxin specifically dedicated to aesthetic use.